Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7901293 | 0.84 | HDAC4 (0.41) | AOC3HTR2B | |
| SCHEMBL29671518 | 0.82 | AOC3 (0.46) | AOC3SLC6A4DHFRHTR6PDE1B | |
| SCHEMBL6203322 | 0.81 | AOC3 (0.53) | AOC3SLC6A4PDE1BPNMTSLC6A2 | |
| SCHEMBL11395224 | 0.79 | AOC3 (0.51) | AOC3SLC6A4PDE1BPNMTSLC6A2 | |
| SCHEMBL24434518 | 0.79 | AOC3 (0.44) | AOC3SLC6A4DHFRHTR6HTR2C | |
| SCHEMBL2601111 | 0.78 | PNMT (0.47) | AOC3SLC6A4PDE1BPNMTSLC6A2 | |
| SCHEMBL29428797 | 0.78 | PGR (0.47) | AOC3SLC6A4PNMTSLC6A2SLC6A3 | |
| SCHEMBL22964291 | 0.78 | TSHR (0.40) | AOC3 | |
| SCHEMBL22964350 | 0.78 | TSHR (0.40) | AOC3 | |
| SCHEMBL254476 | 0.78 | PGR (0.47) | AOC3SLC6A4PNMTSLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-8722942-B2 | Method for producing biphenyl derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2075241-B1 | METHOD FOR PRODUCING A BIPHENYL DERIVATIVE | TORAY FINECHEMICALS CO LTD (JP) | 2013-09-25 | — | — | EP | disclosed |
| US-20100230634-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | Hayashi, Tamio (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2075241-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2009-07-01 | — | — | EP | disclosed |
| EP-0531715-B1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL CO (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5426237-A | Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde | SUMITOMO CHEMICAL CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100230634-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | CYP2E1, DDT, B2M | AOC3 1215/4885SLC6A4 3842/4885DHFR 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.